Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study
- Citation:
- J Clin Oncol vol 26 (28) 4603-4609
- Year:
- 2008
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Leuk Corr Sci
- Sec. Committees:
- Pharmas:
- Grants:
- CA16058, CA101140, CA77658, CA114725, CA31946
- Corr. Author:
- Authors:
- Andreas Neubauer Kati Maharry Krzysztof Mrózek Christian Thiede Guido Marcucci Peter Paschka Robert J. Mayer Richard A. Larson Edison T. Liu Clara D. Bloomfield
- Networks:
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-8525, CALGB-8765, CALGB-8461, CALGB-9665
- Phases:
- 3, N/A
- Keywords:
- Hematologic Malignancies